This message contains images. If you don't see images, click here to view.
Click
here to advertise in this news brief.
|
|
|
|
|
UPCOMING EVENTS IN TRANSPLANTATION
|
Demystifying FQAPI and the new Mitigating Factors regulation – TODAY at NOON (EST)
AST
Please join us as we review the Focused Quality Assessment and Performance Improvement Survey (FQAPI) pilot program and plans for 2015. This free webinar will highlight the link between QAPI and the mitigating factors process.
This free webinar will be held on Friday, Jan. 30, 2015 at 12 p.m. EST (noon), and is open to all transplant professionals. Register today: https://cc.readytalk.com/r/cyowqfdtiqzr&eom.
Free February Webinars
AST
Multiorgan Transplantation: One Organ Too Many? Tuesday, Feb. 10, 3 p.m. EST.
Register today at www.myAST.org/T3 - free for AST members. A review of the current data and experience with combined liver and kidney transplantation, exploring the controversial topics of when to allocate a kidney to candidates with liver failure and acute kidney injury.
Medically Complex Living Donors: Candidacy, Care, and Informed Consent: Tuesday, Feb. 17, 2 p.m. EST.
Register today at www.myAST.org/T3 - free for AST members. Distinguish between “low risk donors” and medically complex living donors, evaluate the meanings of new studies regarding donor risk, and refine the current informed consent process in light of the evolving data.
PRODUCT SHOWCASE
 |
|
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
|
|
Quantifying renal allograft loss following early antibody-mediated rejection
American Journal of Transplantation
Unlike antibody-mediated rejection (AMR) with clinical features, it remains unclear whether subclinical AMR should be treated, as its effect on allograft loss is unknown. It is also uncertain if AMR's effect is homogeneous across donor (deceased/live) and (HLA/ABO) antibody types. We compared 219 patients with AMR (77 subclinical, 142 clinical) to controls matched on HLA/ABO-compatibility, donor type, prior transplant, panel reactive antibody (PRA), age and year.
|
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
LEARN MORE
|
|
To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE
|
|
A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
The Journal of Heart and Lung Transplantation
The appropriate selection of lung transplant recipients is an important determinant of outcomes. This consensus document is an update of the recipient selection guidelines published in 2006. The Pulmonary Council of the International Society for Heart and Lung Transplantation (ISHLT) organized a Writing Committee of international experts to provide consensus opinion regarding the appropriate timing of referral and listing of candidates for lung transplantation. A comprehensive search of the medical literature was conducted with the assistance of a medical librarian. Writing Committee members were assigned specific topics to research and discuss. The Chairs of the Writing Committee were responsible for evaluating the completeness of the literature search, providing editorial support for the manuscript, and organizing group discussions regarding its content.
Predicting graft loss by 1-year in pediatric heart transplant candidates: An analysis of the PHTS database
Circulation via PubMed
Pediatric data regarding the impact of pre-heart transplant (HTx) risk factors on early post-HTx outcomes remain inconclusive. Thus, among patients with previous congenital heart disease (CHD) or cardiomyopathy (CMP), disease-specific risk models for graft loss were developed using pre-HTx recipient and donor characteristics. Patients enrolled in the Pediatric Heart Transplant Study (PHTS) from 1996-2006 were stratified by pre-HTx diagnosis into CMP and CHD cohorts. Logistic regression identified independent, pre-HTx risk factors. Risk models were constructed for 1-year, post-HTx graft loss.
Compared efficacy of preservation solutions in liver transplantation: A long-term graft outcome study from the European Liver Transplant Registry
American Journal of Transplantation
Between 2003 and 2012, 42 869 first liver transplantations performed in Europe with the use of either University of Wisconsin solution (UW; N = 24 562), histidine-tryptophan-ketoglutarate(HTK; N = 8696), Celsior solution (CE; N = 7756) or Institute Georges Lopez preservation solution (IGL-1; N = 1855) preserved grafts. Alternative solutions to the UW were increasingly used during the last decade. Overall, 3-year graft survival was higher with UW, IGL-1 and CE (75 percent, 75 percent and 73 percent, respectively), compared to the HTK (69 percent) (p < 0.0001).
Missed last week's issue? See which articles your colleagues read most.
The safety and efficacy of splenic artery embolization for portal hyperperfusion in liver transplant recipients: A 5-year experience
Liver Transplantation
Severe portal hyperperfusion after liver transplantation has been shown to cause intrahepatic arterial vasoconstriction secondary to increased adenosine washout (hepatic artery buffer response). Clinically, post-transplant portal hyperperfusion can cause severe cases of refractory ascites and hydrothorax. In the past we reported our preliminary experience with the use of splenic artery embolization (SAE) as a way to reduce portal hyperperfusion. Here we present our 5-year experience with SAE in OLT. 681 patients underwent OLT at our institution between January, 2007 and December, 2011.
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
